This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M . Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: 214–226.
Garcia R, Hernandez JM, Caballero MD, Gonzalez M, San Miguel JF . Immunoblastic lymphoma and associated non-lymphoid malignancies following two cases of Waldenstrom's macroglobulinemia. A review of the literature. Eur J Haematol 1993; 50: 299–301.
Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, Siakantaris P, Kontopidou FN, Dimopoulou MN et al. Waldenstrom's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001; 80: 722–727.
Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ . Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 2003; 120: 246–253.
Jermann M, Jost LM, Taverna C, Jacky E, Honegger HP, Betticher DC et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15: 511–516.
Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24: 2343–2351.
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.
Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582.
Tomonari A, Iseki T, Ooi J, Takahashi S, Ishii K, Takahashi T et al. Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan. Int J Hematol 2002; 76: 354–359.
Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–1777.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamamoto, R., Takaori-Kondo, A., Kanda, J. et al. Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant 41, 591–593 (2008). https://doi.org/10.1038/sj.bmt.1705944
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705944
This article is cited by
-
Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique
Bone Marrow Transplantation (2012)